Investing.com - Financial Markets Worldwide

Creo Medical announces UK, EU launch of SpydrBlade Flex

Published 20/03/2025, 08:10
Creo Medical announces UK, EU launch of SpydrBlade Flex
CREO
0.00%

LONDON - Creo Medical (TASE:BLWV) Group plc (AIM: CREO), a medical device company specializing in surgical endoscopy, has launched its SpydrBlade Flex (NASDAQ:FLEX) technology in the UK and Europe, with St Mark’s Hospital in NW London becoming its first commercial customer. The hospital, recognized by the World Endoscopy Organisation as a center of excellence, is already a user of Creo’s Speedboat UltraSlim device.

The SpydrBlade Flex is a multi-modal endoscopic device designed for precision in lower gastrointestinal colorectal resections. Following extensive pre-launch clinical trials globally, the device is now entering the commercial market.

Creo plans to expand the commercial availability of SpydrBlade Flex through its sales channels in the UK, EU, and other international territories, pending local regulatory approvals including from the US Food and Drug Administration (FDA).

The technology will be featured at the upcoming European Society of Gastrointestinal Endoscopy (ESGE) Days 2025 conference in Barcelona, scheduled for April.

CEO Craig Gulliford expressed optimism about the device’s potential to improve patient care for a variety of conditions, from cancers to swallowing disorders, and its role in treating bariatric conditions. Gulliford also highlighted the product’s ability to shift care from the operating theater to the endoscopy room, which could help reduce surgical waiting lists not only in the NHS but globally.

Creo Medical anticipates increased adoption of the SpydrBlade Flex following further regulatory clearances, including FDA approval for a US commercial launch.

The company’s statement emphasized the SpydrBlade Flex as an advanced surgical tool, reflecting Creo’s commitment to pioneering technology in minimally invasive endoscopic instruments.

The information in this article is based on a press release statement from Creo Medical Group plc.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.